EFIS-EJI Ruggero Ceppellini Advanced School of Immunology
La Scuola Superiore d’Immunologia Ruggero Ceppellini
Presents an Advanced EFIS-EJI Course on:

**Tumour Immunology: from tissue microenvironment to immunotherapy**

Directors: Catherine Sautès-Fridman*, Wolf Fridman*, and Ennio Carbone¹

* Université Paris Descartes, Paris F-75006, France, ¹ Università Magna Greacia di Catanzaro 88100, Italy

Centro Congressi Universita’ di Napoli Federico II

Naples, 16 - 18 October, 2017

After decades of frustration the ‘use’ of the immune system to cure us from within has come to age with the spectacular success of new cancer immunotherapies. It could not be a better timing to discuss these themes in a former church given to the University in 1907.

Fellowships available !!. Deadline for application is 15 July 2017.

For registration go to: [https://www.ceppellini.it/up-coming-courses](https://www.ceppellini.it/up-coming-courses)
Programme

Catherine Sautès-Fridman, Paris
Tumour architecture, from response to escape

Wolf Fridman, Paris
Tumour microenvironments in prognosis and therapy

Vincenzo Bronte, Verona
Immunosuppressive monocytes in cancer

Ennio Carbone, Stockholm
NK cells in cancer

Soldano Ferrone, Boston
T cells and MHC in cancer

Zlatko Trajanoski, Graz
Bioinformatics approaches

Alberto Mantovani, Milano
Tumour Macrophages

Hergen Spits, Amsterdam
Innate Lymphoid Cells

Laurence Zitvogel, Paris
Inflammation and microbiota in cancer progression and therapy

Ugur Sahin, Mainz
Individualized cancer RNA vaccines

Federica Cavallo, Torino
Breast carcinoma vaccine in vivo models

Jim Allison, Houston
Immune checkpoint inhibitors (TBC)

Rolf Kiessling, Stockholm
Immune checkpoint inhibitors

Michele Maio, Siena
Immune checkpoint inhibitors

Lorenzo Moretta, Roma
NK cells in adoptive therapy for Acute Myeloid Leukaemia

Pad Sharma, Houston
Immune resistance in genitourinary cancers (TBC)

The Registration Fee of €550,00 includes: all course material, lunches, coffee breaks, welcome buffet. A limited number of partial or full EFIS fellowships is available, with preference given to applicants from developing countries.

Local Organizing Committee: Francesco Colucci, Francesca De Rosa, Silvia Fontana, Riccardo Zappacosta.
www.ceppellini.it
Organising Secretariat: info@frcongressi.it

The Course takes place in memory and in honour of the Ceppellini School Founder Professor Serafino Zappacosta.

The Course Program:

October 16
08.30-08.45 Registration
08.50-09.00 Silvia Fontana-Zappacosta (Naples, Italy) Welcome and the History of Ceppellini Advanced Immunology School
09.00-10.00 Keynote Lecture TBA
10.00-10.20 Coffee break
10.20-11.30 Catherine Sautès-Fridman (Paris, France) Course presentation and Lecture: The tumor microenvironment architecture, from response to escape
11.30-12.30 Wolf Fridman (Paris, France): Tumor microenvironments: prognostic and theranostic impacts
12.30-13.30 Lunch with the speakers and Discussions
13.30-14.30 Zlatko Trajanoski (Graz, Austria) Bioinformatics approaches to study the TME
14.30-15.30 Alberto Mantovani (Milan, Italy) Macrophages 1 and 2 and tumorigenesis
15.30-16.30 Vincenzo Bronte (Verona, Italy) Immunosuppressive monocytes in cancer
16.30-16.50 Coffee Break
16.50-19.00 Free time
19.00-21.00 Welcome party

October 17
08.30-9.30 Hergen Spits (Amsterdam, Netherland) ILC and Cancer
09.30-10.30 Ennio Carbone (Catanzaro, Italy) NK cells and Cancer
10.30-10.50 Coffee Break
10.50-11.50 Soldano Ferrone (Boston, MA, USA) MHC-I and Tumors
11.50-12.50 Laurence Zitvogel (Paris, France) Inflammation and microbiota in cancer progression and therapy
12.50-13.50 Lunch with the speakers and Discussions
13.50-14.50 Ugur Sahin (Mainz, Germany) Tumor Vaccine RNA
14.50-15.50 Federica Cavallo (Turin, Italy) Vaccine DNA in vivo studies
15.50-16.10 Rolf Kiessling (Stockholm, Sweden) Immune check point therapy and MSC
16.10-18.00 Poster Session

October 18
08.30-09.30 Lorenzo Moretta (Rome, Italy) NK cells in AML therapy
09.30-10.30 Michele Maio (Siena, Italy) The anti immune checkpoint therapy in solid tumors (NIBIT).
10.30-12.00 Round table discussion: Immunotherapy: what’s next?